Group 1 - Roche Pharmaceuticals announced that the phase III persevERA study of giredestrant in combination with palbociclib for first-line estrogen receptor-positive/HER2-negative metastatic breast cancer did not meet the primary endpoint of progression-free survival, despite observing numerical benefits [1]